[Pharmacokinetic and clinical evaluations of flomoxef in neonates].
To evaluate pharmacokinetics and clinical efficacy of flomoxef (6315-S, FMOX) in neonates, FMOX was administered to 21 neonates. With 20 mg/kg and 40 mg/kg of intravenous drip-infusion of FMOX 60 minutes, half lives (T 1/2's) was 64.9 minutes and 130.3 minutes, respectively, and when 20 mg/kg of FMOX was infused intravenously to 2 cases, half lives were 70.8 minutes and 110.1 minutes, respectively. When 45-100 mg/kg of FMOX was administered to 17 neonates with infections (pneumonia 8, sepsis 1, sepsis suspected 2, intrauterine infection 2, urinary tract infection 2, omphalitis 2), the efficacy rate was 88.2% (15 of 17). No adverse reactions were observed clinically in the 21 neonates. Transient elevation of eosinophilia was observed in 1 case and transient elevation of S-GOT and S-GPT 1 in another. These results suggest that FMOX is an effective and safe antibiotic to use in neonates.
Ihara
T
T
Department of Pediatrics, Mie National Hospital.
Kamiya
H
H
Matsuda
T
T
Shimizu
S
S
Nishi
H
H
Inamochi
H
H
Taki
N
N
Suzuki
M
M
Kojima
M
M
Kawasaki
H
H
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D002511:Cephalosporins / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004341:Drug Evaluation; D004802:Eosinophilia / Q000139:chemically induced; D005260:Female; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D008297:Male
D002511:Cephalosporins; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C045693:flomoxef